Cassava Sciences Inc (SAVA)
$12.76
2.68 (26.59%)
SAVA Stock Quote Delayed 30 Minutes
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
535.54M
PE Ratio
-20.25
EPS
-0.63
Volume (Avg. Vol.)
4.00M
Day's Range
$10.42 - $13.40
52-Week Range
$8.79 - $32.10
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and Cassava Sciences Inc News
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.
Cassava Sciences Can Recover Despite Harsh Allegations
SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right.
Cassava Stock Is a Bold Play That Could Pay Off Soon
Bears are attacking Cassava as it questions the quality of its clinical data and try to stop its study for treating Alzheimer’s disease.
Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy
Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well. Even after it 57%+ price haircut, approach SAVA stock cautiously.
Fraud Allegations Are Unlikely to Keep Cassava Stock Down
Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops.
Wait to See How the Cassava Sciences Allegations Pan Out
Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result. Is this a buy-on-the-dip moment?
Scrutiny Makes Cassava Sciences Stock a ‘Blood in the Street’ Opportunity
Cassava Sciences stock crashed after a lawyer sought to stop studies of the biotech’s experimental Alzheimer’s treatment. That just makes SAVA stock a better opportunity.
Insiders Like Cassava Sciences, Which Might Be Good News
Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today?
Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity
Amid a regulatory tug-of-war over a proposed Alzheimer's disease treatment, SAVA stock has become a speculator's playground.
Why Traders Shouldn’t Bargain Hunt in Cassava Stock
Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents.
SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations
Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday.
SAVA Stock: The Allegations That Have Cassava Sciences Sinking Today
Shares of SAVA stock are crashing on Wednesday after allegations about Cassava Sciences' Alzheimer's disease treatment are being reviewed.
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're halfway through the week and what better way to begin the day than with a look at the biggest pre-market stock movers for Wednesday!
Cassava Sciences Has an Admirable Goal at Too High a Price
It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No.
Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth
With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits.
